Access to etripamil nasal spray (NS), pending etripamil NS market approval

Patient Access

Until etripamil nasal spray (NS) receives market approval from the FDA, Milestone can provide etripamil NS only through clinical trials. Milestone will consider expanded access requests from other countries where such programs are available.

If you are interested in participating in a clinical trial, please contact your physician.

For additional information on etripamil NS clinical trials, you can also consult

To find out more about the clinical program involving etripamil NS, or for any other questions regarding access to etripamil NS, you can also contact Milestone Pharmaceuticals at:

You will receive a response in approximately 5 business days.